OR WAIT null SECS
© 2021 MJH Life Sciences and Cancer Network. All rights reserved.
© 2021 MJH Life Sciences™ and Cancer Network. All rights reserved.
Experts focus in on optimizing the use of minimal residual disease as a tool to guide decision making in the adjuvant setting for patients at risk for recurrence with colorectal cancer.
March 26th 2021
Christopher Lieu, MD, discusses the standard of care for genomic profiling in early stage CRC.
April 26th 2021
Daniel Ahn, DO, reviews MRD as a novel approach to assessing risk for recurrence and response to treatment in early stage CRC.
May 21st 2021
A leader in diagnosis and management of CRC reviews the role of MRD testing in early stage CRC.
June 25th 2021
Dr. Daniel Ahn discusses the implications of postoperative ctDNA testing for decision-making in early stage CRC.
July 23rd 2021
An expert in CRC describes key findings from clinical trials related to personalized detection of molecular recurrence in early stage CRC.
August 20th 2021
Dr. Christopher Lieu shares his insights into gaps in care in the adjuvant setting in colorectal cancer.
This article reviews MRD and decision-making in early-stage colorectal cancer and includes insights from Christopher Lieu, MD, of the University of Colorado School of Medicine in Denver, and Daniel Ahn, DO, of the Mayo Clinic in Phoenix, AZ.